Transgene Biotek (BOM:526139) Cyclically Adjusted PB Ratio: (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:526139 Transgene Biotek Ltd BOM:526139
54 GF Score
Price ₹2.90
GF Value ₹4.25
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Transgene Biotek Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Transgene Biotek  (BOM:526139) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Transgene Biotek Cyclically Adjusted PB Ratio Related Terms


Transgene Biotek Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Transgene Biotek's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Biotek Cyclically Adjusted PB Ratio Chart

Transgene Biotek Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.07 0.07

Transgene Biotek Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.11 0.00 0.07 0.00

BOM:526139 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Transgene Biotek's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transgene Biotek Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene Biotek's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Transgene Biotek's Cyclically Adjusted PB Ratio falls into.


BOM:526139
54GF Score
Transgene Biotek Ltd BOM:526139
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgene Biotek Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Transgene Biotek's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Transgene Biotek's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Transgene Biotek Quarterly Data

Book Value per Share CPI Adj_Book
201212 97.148 83.774 194.074
201303 48.949 85.687 95.603
201403 27.184 91.425 49.762
201503 25.259 97.163 43.507
201603 23.023 102.518 37.584
201703 7.769 105.196 12.360
201803 6.919 109.786 10.547
201806 0.000 111.317 0.000
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 5.759 118.202 8.154
201906 0.000 120.880 0.000
201909 5.031 123.175 6.836
201912 0.000 126.235 0.000
202003 4.312 124.705 5.787
202006 0.000 127.000 0.000
202009 3.611 130.118 4.644
202012 0.000 130.889 0.000
202103 2.935 131.771 3.728
202106 0.000 134.084 0.000
202109 2.247 135.847 2.768
202112 0.000 138.161 0.000
202203 2.293 138.822 2.764
202206 0.000 142.347 0.000
202209 -0.443 144.661 -0.513
202212 0.000 145.763 0.000
202303 1.500 146.865 1.709
202306 0.000 150.280 0.000
202309 1.465 151.492 1.618
202312 0.000 152.924 0.000
202403 1.414 153.035 1.546
202406 0.000 155.789 0.000
202409 1.430 157.882 1.516
202412 0.000 158.323 0.000
202503 1.324 157.552 1.406
202506 0.000 159.755 0.000
202509 1.215 162.289 1.253
202512 0.000 163.281 0.000
202603 1.106 164.272 1.127
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Transgene Biotek (BOM:526139) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene Biotek stock appears to be undervalued. The current stock price of ₹2.90 is trading 31.8% below its estimated GF Value™ of ₹4.25. GuruFocus considers Transgene Biotek to be Possible Value Trap.

Key valuation signals for BOM:526139:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹4.25 vs. price of ₹2.90 (31.8% below fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the BOM:526139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Transgene Biotek Business Description

Address Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.
54GF Score

Get the complete analysis for BOM:526139

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.90
Price
₹4.25
GF Value